Novartis: Sandoz psoriasis generic matches Humira profile.
(CercleFinance.com) - Novartis' Sandoz generics unit said on Thursday that its proposed biosimilar psoriasis drug matches reference medicine Humira in terms of efficacy and safety.
Data from a long-term study has showed that the profiles of adalimumab and Abbvie's Hulira matched after 51 weeks of treatment in patients with moderate-to-severe chronic plaque psoriasis.
Adalimumab is currently being reviewed by the European Medicines Agency.
Sandoz plans to launch five major oncology and immunology biosimilars between 2017 and 2020, including adalimumab.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Data from a long-term study has showed that the profiles of adalimumab and Abbvie's Hulira matched after 51 weeks of treatment in patients with moderate-to-severe chronic plaque psoriasis.
Adalimumab is currently being reviewed by the European Medicines Agency.
Sandoz plans to launch five major oncology and immunology biosimilars between 2017 and 2020, including adalimumab.
Copyright (c) 2017 CercleFinance.com. All rights reserved.